TOTAL: $11M
Year to Date: $137.23M

Company
(Symbol)#*

Partner
(Country)

Amt.
(M)

Triggering
Event

Details (Date)


Idenix
Pharmaceuticals
Inc.
(IDIX)

Novartis Pharma AG
(Switzerland)

ND

Milestone payment

Idenix received the milestone payment after the European Commission approved Sebivo for chronic hepatitis B (4/30)

MediVas LLC*

Merck & Co. Inc.

ND

Milestone payment

MediVas achieved the milestone based on one of its orally available biologics that is the focus of the collaboration (4/3)

Montigen
Pharmaceuticals
Inc.
's shareholders

SuperGen Inc.

(SUPG)

$10

Milestone payment

FDA clearance for the start of a Phase I trial of MP470 for cancer triggered the payment to shareholders of Montigen, which SuperGen acquired in January 2006 (4/27)

Pharmacopeia
Drug Discovery
Inc.
(PCOP)

Schering-Plough
Corp.

$1

Milestone payment

Pharmacopeia earned a $1M milestone payment for the advancement of a compound into preclinical development (4/17)


Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
* Private company.
Currency conversions are based on exchange rates at the time of the deal.
ND = Not disclosed.

No Comments